Triazolylated teritiary amine compound or salt thereof
    2.
    发明授权
    Triazolylated teritiary amine compound or salt thereof 失效
    三唑基化三胺化合物或其盐

    公开(公告)号:US5674886A

    公开(公告)日:1997-10-07

    申请号:US199180

    申请日:1994-02-24

    摘要: A triazolylated tertiary amine compound represented by general formula (I) or a salt thereof, having an aromatase inhibitory activity and being useful for preventing and treating breast cancer, mastopathy, endometriosis, prostatomergaly, etc., wherein A represents a single bond, lower alkylene or carbonyl; B represents lower alkyl, aryl, a 5- or 6-membered heterocyclic group, or a bicyclic fused heterocyclic group; D represents aryl, a 5- or 6-membered heterocyclic group, or a bicyclic fused heterocyclic group; and E represents 4H-1,2,4-triazolyl, 1H-1,2,4-triazolyl or 1H-1,2,3-triazolyl.

    摘要翻译: PCT No.PCT / JP92 / 01089 Sec。 371日期1994年2月24日 102(e)1994年2月24日PCT PCT 1992年8月27日PCT公布。 公开号WO93 / 05027 (I)具有芳香酶抑制活性的通式(I)表示的三唑基化叔胺化合物或其盐,可用于预防和治疗乳腺癌,乳腺病,子宫内膜异位症,前列腺素, 等等,其中A表示单键,低级亚烷基或羰基; B表示低级烷基,芳基,5或6元杂环基或双环稠合杂环基; D表示芳基,5或6元杂环基或双环稠合杂环基; E表示4H-1,2,4-三唑基,1H-1,2,4-三唑基或1H-1,2,3-三唑基。

    Azole derivative and pharmaceutical composition thereof
    3.
    发明授权
    Azole derivative and pharmaceutical composition thereof 失效
    唑衍生物及其药物组合物

    公开(公告)号:US5807880A

    公开(公告)日:1998-09-15

    申请号:US619629

    申请日:1996-03-26

    摘要: An azole derivative represented by the following general formula (I) ##STR1## (symbols in the formula have the following meanings; R.sup.1 and R.sup.2 : the same or different from each other and each represents a hydrogen atom, a lower alkyl group or a phenyl group which may be substituted with a halogen atom, A, B and D: the same or different from one another and each represents a group represented by the formula ##STR2## or a nitrogen atom, X and Y: the same or different from each other and each represents a single bond, a methylene group, an oxygen atom, a group represented by a formula S(O).sub.n, or a group represented by the formula ##STR3## R.sup.3 and R.sup.4 : the same or different from each other and each represents a hydrogen atom or a lower alkyl group, and n: 0, 1 or 2), a salt thereof, a hydrate thereof or a solvate thereof. This compound has a function to inhibit steroid 17-20 lyase and is useful as preventive and treating agents for prostatic cancer, prostatic hypertrophy, virilism, breast cancer, mastopathy, histeromyoma, and endometriosis.

    摘要翻译: PCT No.PCT / JP94 / 01593 Sec。 371日期:1996年3月26日 102(e)1996年3月26日PCT 1994年9月28日PCT公布。 出版物WO95 / 09157 日期:1995年4月6日由以下通式(I)表示的唑衍生物(I)(式中的符号具有以下含义:R 1和R 2彼此相同或不同,各自表示氢原子 可以被卤素原子取代的低级烷基或苯基,A,B和D:彼此相同或不同,并且各自表示由下式表示的基团或氮原子,X和 Y:彼此相同或不同,并且各自表示单键,亚甲基,氧原子,由式S(O)n表示的基团或由下式表示的基团:R 3和R 4: 相同或不同,各自表示氢原子或低级烷基,n:0,1或2),其盐,其水合物或其溶剂合物。 该化合物具有抑制类固醇17-20裂解酶的功能,可用作前列腺癌,前列腺肥大,病毒性,乳腺癌,乳腺病,囊胚瘤和子宫内膜异位症的预防和治疗剂。

    Dihydropyridine-3, 5-dicarboxylic acid ester derivatives
    9.
    发明授权
    Dihydropyridine-3, 5-dicarboxylic acid ester derivatives 失效
    二氢吡啶-3,5-二羧酸酯衍生物

    公开(公告)号:US5616715A

    公开(公告)日:1997-04-01

    申请号:US491793

    申请日:1995-06-19

    摘要: A process is provided for producing diastereoisomer A or a pharmaceutically acceptable acid addition salt of 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-(1-benzylpyrrolidin-3-yl) ester 5-methyl ester which comprises subjecting a mixture of diastereoisomers A and B of 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-(1-benzylpyrrolidin-3-yl) ester 5-methyl ester to column chromatography using silica gel as a carrier and a mixture of ethyl acetate and acetic acid as an eluant, and then separating the acetate of diastereoisomer A from the eluate, or treating the acetate with a base, or further treating the resulting diastereoisomer A with a pharmaceutically acceptable acid.

    摘要翻译: 提供了一种制备非对映异构体A或2,6-二甲基-4-(3-硝基苯基)-1,4-二氢吡啶-3,5-二羧酸的3-(1-苄基吡咯烷-3-基) - 基)酯5-甲酯,其包括使2,6-二甲基-4-(3-硝基苯基)-1,4-二氢吡啶-3,5-二羧酸3-(1- 苄基吡咯烷-3-基)酯将5-甲酯与硅胶作为载体和乙酸乙酯与乙酸的混合物作为洗脱剂进行柱色谱分离,然后将非对映异构体A的乙酸酯与洗脱液分离,或用 碱,或用药学上可接受的酸进一步处理所得的非对映异构体A.